Marker Therapeutics Shares Double After Hours, FDA Approves IND for MT-601

 Shares of Marker Therapeutics Inc. jumped in after-hours trading Thursday, following news the U.S. Food and Drug Administration approved the company's investigational new drug application for MT-601 to treat certain patients with non-Hodgkin lymphoma.

At 5:54 p.m. ET, the company's shares were trading 100% higher at 66 cents a share. Volume in the after-hours market was over 2.4 million shares.

Peter L. Hoang, the company's president and chief executive, said, "FDA clearance of our IND for MT-601 is a significant milestone as we advance our pipeline in a number of company-sponsored trials." He added that MT-601 targets six tumor-associated antigens highly expressed in lymphoma, and said, "we look forward to initiating our company-sponsored Phase 1 study next year."

https://www.marketscreener.com/quote/stock/MARKER-THERAPEUTICS-INC-46699740/news/Marker-Therapeutics-Shares-Double-After-Hours-FDA-Approves-IND-for-MT-601-41208644/